Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis

Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor

SAN FRANCISCO , Aug. 22, 2025 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision therapies for neurodegenerative diseases, today announced it has been awarded a $49.2 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to support a Phase 2 clinical trial of LHP588 in Alzheimer's disease (AD) patients with a confirmed Porphyromonas gingivalis ( P. gingivalis ) infection. P. gingivalis is best known for its role as a keystone pathogen in chronic periodontitis and has been implicated in chronic systemic inflammation and cognitive decline.

LHP58